GlobeNewswire Inc.··Sanofi And RegeneronDupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline
Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent